Cardiex Limited (AU:CDX) has released an update.
Cardiex Limited is poised for a record-breaking year with anticipated revenues exceeding $11 million, buoyed by strong clinical trial services and various product launches, including the Pulse biometric monitor. The company’s product, CONNEQT Pulse, has been endorsed by the American Medical Association and is backed by recent funding rounds and financial support from C2 Ventures. Cardiex is also planning to expand its consumer reach with upcoming FDA clearances, e-commerce platforms, and a nationwide telehealth network.
For further insights into AU:CDX stock, check out TipRanks’ Stock Analysis page.
